FDA Seeks Public Input on Guardrails for Generative AI in Healthcare
The FDA is moving to shape how generative AI will be overseen in healthcare by asking the public and industry for input on regulatory approaches. The agency wants feedback on key questions around safety, efficacy, and accountability for AI tools that can generate text, images, or recommendations used in clinical decision-making.
The request reflects growing recognition that existing medical device regulations — designed largely for static, single-purpose software — may not fully accommodate AI systems that can learn, adapt, and produce variable outputs. Generative AI in medicine spans a wide range of applications, from drafting clinical notes and summarizing patient records to assisting with diagnostic imaging interpretations.
Industry observers note that the FDA's approach signals it is trying to balance fostering innovation with ensuring patient safety. The agency has already cleared several AI-enabled medical devices under existing pathways, but generative AI introduces new complexities around transparency, bias, and ongoing performance monitoring.
The comment period is expected to draw input from healthcare providers, AI developers, patient advocates, and researchers, with the resulting guidance likely to influence how the next generation of medical AI products comes to market.